Everything below concerns glucagon receptor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-05-09. Numbers and descriptions here follow the published literature rather than marketing material.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 4,700 Da | Peptide of roughly forty amino acids |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist class |
| Research code | LY3437943 | Internal development designation |
| Compound class | Incretin mimetic peptide | Synthetic, not a biologic extract |
| Development status | Investigational | No general regulatory approval |
供应环节涉及来源核实与文件审核两类工作。分析证书、批次记录以及第三方检测报告构成常见的可追溯材料。来源不清的样品很难确认身份与纯度，因此核实步骤在实际操作中具有明确意义。缺少方法细节的报告通常无法复核。
多肽类化合物的表征通常依赖色谱与质谱联用技术。反相高效液相色谱用于评估纯度与有关物质，质谱用于确认分子量，肽图分析通过酶解碎片比对验证一级结构。这些手段组合使用，可以把目标产物与降解产物或类似物区分开来。单一方法往往不足以完成完整确认。
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
== History == A-69024 was first described in the scientific literature by 1989. It was under development by Abbott Laboratories. The drug reached the preclinical research stage of development prior to the discontinuation of its development in 1994.
== History == The origin of the term food noise is unknown, but it first appeared in a Google search in 2006. Google searches for “food noise” increased markedly in 2022, possibly due to the rising use of GLP-1 receptor agonist drugs (GLP-1 RA drugs) for weight loss. Growing public interest spurred attention from researchers, and the concept was first incorporated into a model of food cue reactivity (how the body and brain respond when a person sees, smells, or thinks about food) in 2023. However, other researchers do not see food cue reactivity as the sole trigger for food noise.
Ornithine is a non-proteinogenic α-amino acid that plays an essential role in the urea cycle (to the extent that it is sometimes also called the Ornithine Cycle). Improper levels can cause disorders of the urea cycle, such as hyperornithinemia, hyperammonemia as well as other metabolic diseases such as gyrate atrophy and cancer. The name "ornithine" originates from the Greek word for bird (ornis or ornith-) in reference to its discovery as a benzoate ester in chicken excrement, by Max Jaffe in 1877. It is a key substrate for the biosynthesis of proline, polyamines and citrulline, but as a non-essential amino acid it is not incorporated into proteins in humans. The moiety derived from ornithine is called ornithyl.
Most steroid users are not athletes. In the United States, between 1 million and 3 million people (1% of the population) are thought to have used AAS. Studies in the United States have shown that AAS users tend to be mostly middle-class men with a median age of about 25 who are noncompetitive bodybuilders and non-athletes and use the drugs for cosmetic purposes. "Among 12- to 17-year-old boys, use of steroids and similar drugs jumped 25 percent from 1999 to 2000, with 20 percent saying they use them for looks rather than sports, a study by insurer Blue Cross Blue Shield found." Another study found that non-medical use of AAS among college students was at or less than 1%. According to a recent survey, 78.4% of steroid users were noncompetitive bodybuilders and non-athletes, while about 13% reported unsafe injection practices such as reusing needles, sharing needles, and sharing multidose vials, though a 2007 study found that sharing of needles was extremely uncommon among individuals using AAS for non-medical purposes, less than 1%. Another 2007 study found that 74% of non-medical AAS users had post-secondary degrees and more had completed college and fewer had failed to complete high school than is expected from the general populace. The same study found that individuals using AAS for non-medical purposes had a higher employment rate and a higher household income than the general population.
== Society == Mass Party, a political party in Thailand (2006–2009?) Mass society, a society based on relations between huge numbers of people, whose prototypical denizen is the "mass man" Mass politics, politics in the mass society, featuring especially the modern political party
Sources: en.wikipedia.org
=== 2017–2021: Rainier Fog === In January 2017, Mike Inez stated in an interview that the band had begun work on a new album. In June 2017, it was reported that the band would return to Studio X (formerly Bad Animals Studios) in Seattle to record a new album later that month, for a tentative early 2018 release. The sessions were helmed by Nick Raskulinecz, who produced the band's last two albums. Studio X was the studio where Alice in Chains recorded its 1995 self-titled album. According to Inez, the band was not signed to a label, having completed its previous two-record contract with the Universal Music Group. "This [upcoming album], we're not sure where it's gonna land ... I mean, we financed ['Black Gives Way To Blue'] on our own too, so we're not too worried about that stuff. We've just gotta get it out to ... a significant label [with worldwide distribution]." The band started recording their sixth studio album on June 12, 2017. On January 11, 2018, producer Nick Raskulinecz announced via Instagram that the album was nearly finished and that there was only one more day left of recording. During an interview with Guitar World published on April 11, 2018, Jerry Cantrell said that the album was recorded at four studios. After recording at Studio X in Seattle, the band went to Nashville to record vocals and lead guitars at Nick Raskulinecz's home studio. But Cantrell had to take an unexpected break from work for a couple of weeks after getting sick on a trip to Cabo for Sammy Hagar's birthday.
=== Water === Snow and ice sublime gradually at temperatures below the solid–liquid boundary (melting point) (generally 0 °C), and at partial pressures below the triple point pressure of 612 Pa (0.00604 atm), at a low rate. In freeze-drying, the material to be dehydrated is frozen and its water is allowed to sublime under reduced pressure or vacuum. The loss of snow from a snowfield during a cold spell is often caused by sunshine acting directly on the upper layers of the snow. Sublimation of ice is a factor to the erosive wear of glacier ice, known as ablation in glaciology.
Current generation phones, called smartphones, have many functions besides making telephone calls, and therefore have several other radio transmitters and receivers that connect them with other networks: usually a Wi-Fi modem, a Bluetooth modem, and a GPS receiver.
reassociation kinetics The measurement and manipulation of the rate of reannealing of complementary strands of DNA, generally by heating and denaturing a double-stranded molecule into single strands and then observing their rehybridization at a cooler temperature. Because the base pair G+C requires more energy to anneal than the base pair A+T, the rate of reannealing between two strands depends partly on their nucleotide sequence, and it is therefore possible to predict or estimate the sequence of the duplex molecule by the time it takes to fully hybridize. Reassociation kinetics is studied with C0t analysis: fragments reannealing at low C0t values tend to have highly repetitive sequences, while higher C0t values imply more unique sequences.
Sources: en.wikipedia.org
The Ukrainian military announced its withdrawal from the Kanal neighborhood of Chasiv Yar. One person was killed in a Russian missile strike on Odesa, while another person was killed in a separate attack in Donetsk Oblast. The Russian military destroyed a Ukrainian MiG-29 fighter jet in a missile strike at Krivoi Rog Air Base. In Russia, the Tambov Gunpowder plant was struck by HUR drones. Russian officials denied any damage and reported all drones shot down. Civilian videos showed explosions in the area.
diagnosis, prevention, or treatment of disease or impairment health assessments An objective of the CLIA is to ensure the accuracy, reliability, and timeliness of test results regardless of where the test was performed. Most laboratory-developed tests have been regulated under this program. In 2014, the FDA started a public discussion about regulating some LDTs.
== Prizes and awards == 2023: VinFuture, Innovators with Outstanding Achievements in Emerging Fields – Jens Juul Holst, Joel Francis Habener, Daniel Joshua Drucker and Svetlana Mojsov 2023: Nature 10 most influential people who shaped science 2024: Pearl Meister Greengard Prize by the Rockefeller University 2024: Time 100 Most Influential People, Pioneers section 2024: Princess of Asturias Awards, Technical and Scientific Research – Daniel J. Drucker, Jeffrey M. Friedman, Joel F. Habener, Jens Juul Holst and Svetlana Mojsov 2024: Tang Prize, Biopharmaceutical Science – Joel F. Habener, Svetlana Mojsov and Jens Juul Holst 2024: Lasker-DeBakey Clinical Medical Research Award – Joel Habener, Svetlana Mojsov and Lotte Bjerre Knudsen 2024: BBVA Foundation Frontiers of Knowledge Awards - Biology and Biomedicine - Daniel Joshua Drucker, Joel Habener, Jens Juul Holst and Svetlana Mojsov 2025: Breakthrough Prize in Life Sciences - Daniel J. Drucker, Joel Habener, Jens Juul Holst, Lotte Bjerre Knudsen and Svetlana Mojsov; Alberto Ascherio and Stephen L. Hauser; and David R. Liu 2025: Warren Triennial Prize – Joel Habener, Daniel J.
Sources: en.wikipedia.org
It is a synthetic peptide classified as a triple receptor agonist. It engages the GLP-1, GIP, and glucagon receptors at once. It is investigated for metabolic and weight-related conditions rather than approved for general use.
No regulatory agency has approved it for routine medical use. It remains an investigational compound studied in controlled trials. Access outside research settings is not established.
Each receptor influences energy balance through different pathways. Combining them is intended to add fat loss from lowered intake and higher expenditure. The optimal balance among the three effects is still under study.
It is a synthetic peptide triagonist that engages GIP, GLP-1, and glucagon receptors. Investigational compounds in this class are studied for metabolic conditions rather than for a single organ system.